Compare Quest Diagnostics Inc (DGX) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares Core MSCI Emerging Markets ETF — how do they compare? Quest Diagnostics Inc trades at $204.67 (market cap $22.80B), while iShares Core MSCI Emerging Markets ETF trades at $79.97. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while iShares Core MSCI Emerging Markets ETF pays none. Which is the better fit depends on your goals.
| DGX | IEMG | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $216.02 | $86.00 |
52-Week Low | $166.42 | $59.90 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
IEMG is trading at $78.49, down 3.49% over the past 24 hours amid a bearish technical signal. The ETF has delivered strong performance with a 35% surge over the past year, driven by its 40% technology weighting and exposure to South Korean and Taiwanese semiconductor stocks. Recent news highlights record inflows into emerging markets and IEMG's cost advantage over competitors like EEM with its 0.09% expense ratio.
The outlook for IEMG remains mixed with attractive emerging market valuations and AI-driven growth potential balanced against elevated volatility and geopolitical risks. While the fund offers diversified exposure to fast-growing economies, investors face concentration risks in tech stocks and potential headwinds from US-China trade tensions that could impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
